Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

– Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month –

– Part C Portion of Phase 1 Trial of IMU-935 in Psoriasis Patients Ongoing; Data Expected in the Second Half of 2022 –

– Current Cash and Cash Equivalents Expected to Fund Immunic Into the Third Quarter of 2023 –

– Webcast to be Held Today, May 10, 2022, at 8:00 am ET

NEW YORK, May 10, 2022 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2022 and provides a corporate update.

“The first quarter of 2022 was marked by continued momentum, both financially and within our clinical pipeline programs,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “Notably, we extended our cash runway into the third quarter of 2023. The increased funds further solidify our ability to advance our programs and achieve key value inflection points, including next month’s highly-anticipated read-out of top-line data from our phase 2 CALDOSE-1 trial of lead asset, selective oral DHODH inhibitor, vidofludimus calcium (IMU-838), in patients with moderate-to-severe ulcerative colitis (UC).”

“During the most recent period, patient enrollment in both our phase 3 ENSURE program of vidofludimus calcium…

Read more…